Novo Nordisk A S annual total liabilities
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Total Liabilities Growth & History (NVO)
Novo Nordisk A S's total liabilities was kr348.86B for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr348.86B | kr26.71B | +8.29% |
| 2024 | 2024-12-31 | kr322.14B | kr114.22B | +54.93% |
| 2023 | 2023-12-31 | kr207.93B | kr50.15B | +31.79% |
| 2022 | 2022-12-31 | kr157.77B | kr34.01B | +27.48% |
| 2021 | 2021-12-31 | kr123.76B | kr42.16B | +51.67% |
| 2020 | 2020-12-31 | kr81.60B | kr13.58B | +19.96% |
| 2019 | 2019-12-31 | kr68.02B | — | — |
Novo Nordisk A S quarterly total liabilities
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr373.66B | kr59.58B | +18.97% |
| Q1 2026 | 2026-03-31 | kr356.16B | — | — |
| Q4 2025 | 2025-12-31 | kr348.86B | kr26.71B | +8.29% |
| Q3 2025 | 2025-09-30 | kr342.39B | — | — |
| Q2 2025 | 2025-06-30 | kr314.09B | — | — |
| Q4 2024 | 2024-12-31 | kr322.14B | kr114.22B | +54.93% |
| Q4 2023 | 2023-12-31 | kr207.93B | kr50.15B | +31.79% |
| Q4 2022 | 2022-12-31 | kr157.77B | kr34.01B | +27.48% |
| Q4 2021 | 2021-12-31 | kr123.76B | kr42.16B | +51.67% |
| Q4 2020 | 2020-12-31 | kr81.60B | — | — |
Novo Nordisk A S total liabilities trends
Over the last five fiscal years, Novo Nordisk A S's total liabilities increased from kr81.60B to kr348.86B, a change of kr267.26B. The latest reported quarter, Q2 2026, shows kr373.66B.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...